Search

Ella A Ioffe

from Brooklyn, NY
Age ~75
Get Report
Also known as:
Ella A Toffe, Ella Yoffe
Phone and address:
2646 Hubbard St, Brooklyn, NY 11235
(718) 615-0876
Related to:
Barbara Ellen Potter, 73Yan Offe, 52Oskar Ioffe, 79Yan Ioffe, 52
Connected to:
Ilia G Ioffe, 52Michael A Ioffe, 85Nataliya Ioffe, 75Pauline Ioffe, 33Vadim Ioffe, 60Michael D Ioffreda, 61Jeffrey E Ioimo, 38Simona Ioja, 41Dmitriy Iokhvid, 40Toshino Ioki, 68

Ella Ioffe Phones & Addresses

  • 2646 Hubbard St, Brooklyn, NY 11235 (718) 615-0876 (718) 332-7002
  • 2646 Hubbard St APT R, Brooklyn, NY 11235 (917) 379-7164

Resumes

Resumes

Ella Ioffe Photo 1

Director, Immuno-Oncology

View page
Location:
2646 Hubbard St, Brooklyn, NY 11235
Industry:
Biotechnology
Work:
Regeneron Pharmaceuticals, Inc.
Director, Immuno-Oncology
Regeneron Pharmaceuticals, Inc. Jan 1, 2013 - Dec 2018
Associate Director, Oncology and Angiogenesis and Target Gene Delivery
Regeneron Pharmaceuticals, Inc. Jan 2005 - Dec 2012
Senior Staff Scientist, Oncology and Angiogenesis and Target Gene Delivery
Regeneron Pharmaceuticals, Inc. Jan 1, 2000 - Dec 1, 2004
Staff Scientist, Oncology and Angiogenesis
Regeneron Pharmaceuticals, Inc. Jun 1, 1999 - Dec 1, 1999
Scientist, Oncology and Angiogenesis
Education:
Albert Einstein College of Medicine 1990 - 1995
Doctorates, Doctor of Philosophy, Biology Saint Petersburg State Chemical Pharmaceutical Academy 1986 - 1988
Skills:
Oncology
Angiogenesis
Molecular Genetics
Monoclonal Antibodies
Biopharmaceuticals
Assay Development
Biomarkers
Protein Chemistry
Lifesciences
Antibodies
Drug Discovery
Animal Models
Cell
Cell Biology
Life Sciences
Immune Oncology
Cancer Research
Laboratory
Languages:
Russian
English
Ella Ioffe Photo 2

Microbiologist

View page
Location:
New York, NY
Industry:
Hospital & Health Care
Work:
Lifespan
Microbiologist

Publications

Us Patents

Oligonucleotides Of The Ob-R Isoforms And Methods Of Diagnosing Body Weight

View page
US Patent:
7148004, Dec 12, 2006
Filed:
Jan 16, 1997
Appl. No.:
08/783734
Inventors:
Jeffrey M. Friedman - New York NY, US
Gwo-Hwa Lee - New York NY, US
Ricardo Proenca - Astoria NY, US
Ella Ioffe - New York NY, US
Assignee:
The Rockefeller University - New York NY
International Classification:
C12Q 1/68
C07H 21/04
US Classification:
435 6, 536 243, 536 2431
Abstract:
The present invention relates to identification of a receptor for a satiety factor, which is involved in body weight homeostasis. Mutations in this receptor are associated with obese phenotypes. In particular, the present invention relates to identification and characterization of the receptor for leptin, including a naturally occurring soluble form of the receptor that is expected to modulate leptin activity, in particular to agonize leptin activity. The invention further relates to the nucleic acids encoding the receptor, and to methods for using the receptor, e. g. , to identify leptin analogs, therapeutically, such as in gene therapy or in soluble form as an agonist or antagonist of leptin activity, or diagnostically.

Db, The Receptor For Leptin, Nucleic Acids Encoding The Receptor, And Uses Thereof

View page
US Patent:
20070048836, Mar 1, 2007
Filed:
Oct 24, 2006
Appl. No.:
11/585709
Inventors:
Jeffrey Friedman - New York NY, US
Gwo-Hwa Lee - New York NY, US
Ricardo Proenca - Astoria NY, US
Ella Ioffe - New York NY, US
International Classification:
C12P 21/06
C07H 21/04
C07K 14/705
US Classification:
435069100, 435320100, 435325000, 530350000, 536023500
Abstract:
The present invention relates to identification of a receptor for a satiety factor, which is involved in body weight homeostasis. Mutations in this receptor are associated with obese phenotypes. In particular, the present invention relates to identification and characterization of the receptor for leptin, including a naturally occurring soluble form of the receptor that is expected to modulate leptin activity, in particular to agonize leptin activity. The invention further relates to the nucleic acids encoding the receptor, and to methods for using the receptor, e.g., to identify leptin analogs, therapeutically, such as in gene therapy or in soluble form as an agonist or antagonist of leptin activity, or diagnostically.

Novel Il10 Agonists And Methods Of Use Thereof

View page
US Patent:
20210355184, Nov 18, 2021
Filed:
May 11, 2021
Appl. No.:
17/317475
Inventors:
- Tarrytown NY, US
Maria del Pilar MOLINA-PORTELA - Bronx NY, US
Ella IOFFE - Bronx NY, US
Markus MOHRS - Pleasantville NY, US
International Classification:
C07K 14/54
C07K 1/22
A61P 35/00
C07K 16/42
Abstract:
The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.

Non-Human Animals Having A Humanized Cluster Of Differentiation 47 Gene

View page
US Patent:
20210161112, Jun 3, 2021
Filed:
Jan 29, 2021
Appl. No.:
17/161801
Inventors:
- Tarrytown NY, US
Ella Ioffe - Bronx NY, US
Alexander Mujica - Elmsford NY, US
Gavin Thurston - Briarcliff Manor NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A01K 67/027
G01N 33/50
C07K 16/28
C07K 14/705
C07K 14/47
C12N 15/85
Abstract:
Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).

Anti-Ctla-4 Antibodies And Uses Thereof

View page
US Patent:
20210040232, Feb 11, 2021
Filed:
Oct 14, 2020
Appl. No.:
17/070129
Inventors:
- Tarrytown NY, US
Ella IOFFE - Bronx NY, US
Elena BUROVA - Mount Kisco NY, US
Gavin THURSTON - Briarcliff Manor NY, US
William OLSON - Yorktown Heights NY, US
International Classification:
C07K 16/40
C07K 16/28
A61P 35/00
C12N 15/62
Abstract:
The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.

Anti-Lag3 Antibodies And Uses Thereof

View page
US Patent:
20190284277, Sep 19, 2019
Filed:
Jun 6, 2019
Appl. No.:
16/433263
Inventors:
- Tarrytown NY, US
Aynur HERMANN - Jersey City NJ, US
Ella IOFFE - Bronx NY, US
Elena BUROVA - Mount Kisco NY, US
Gavin THURSTON - Briarcliff Manor NY, US
International Classification:
C07K 16/28
A61K 39/395
A61K 45/06
Abstract:
The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

Anti-Ctla-4 Antibodies And Uses Thereof

View page
US Patent:
20190048096, Feb 14, 2019
Filed:
Jul 26, 2018
Appl. No.:
16/046551
Inventors:
- Tarrytown NY, US
Ella IOFFE - Bronx NY, US
Elena BUROVA - Mount Kisco NY, US
Gavin THURSTON - Briarcliff Manor NY, US
William OLSON - Yorktown Heights NY, US
International Classification:
C07K 16/40
C12N 15/62
A61P 35/00
C07K 16/28
Abstract:
The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.

Non-Human Animals Having A Humanized Cluster Of Differentiation 47 Gene

View page
US Patent:
20180249689, Sep 6, 2018
Filed:
May 17, 2018
Appl. No.:
15/982174
Inventors:
- Tarrytown NY, US
Ella Ioffe - Bronx NY, US
Alexander Mujica - Elmsford NY, US
Gavin Thurston - Briarcliff Manor NY, US
Assignee:
REGENERON PHARMACEUTICALS, INC. - Tarrytown NY
International Classification:
A01K 67/027
G01N 33/50
C07K 14/705
C12N 15/85
C07K 16/28
Abstract:
Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
Control profile
Ella A Ioffe from Brooklyn, NY, age ~75 Get Report